Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| UnitedHealth | 9.68% | $33.98M | $309.81B | -33.47% | 72 Outperform | |
| Eli Lilly & Co | 8.39% | $29.46M | $984.63B | 35.16% | 72 Outperform | |
| Regeneron | 6.82% | $23.94M | $80.22B | 5.85% | 78 Outperform | |
| PureCycle Technologies | 5.16% | $18.10M | $1.66B | -9.99% | 38 Underperform | |
| Align Tech | 5.07% | $17.78M | $11.49B | -22.15% | 74 Outperform | |
| Amgen | 4.87% | $17.10M | $172.70B | 24.96% | 77 Outperform | |
| Apellis Pharmaceuticals | 3.63% | $12.74M | $3.15B | -30.87% | 50 Neutral | |
| United Therapeutics | 3.38% | $11.86M | $21.08B | 38.74% | 79 Outperform | |
| Jazz Pharmaceuticals | 3.35% | $11.76M | $10.60B | 36.27% | 64 Neutral | |
| Danaher | 2.96% | $10.40M | $166.25B | -0.63% | 75 Outperform |